Pilot Study on the Effectiveness of Novel Peripherally Inserted Central Catheter (PICC) Securement Dressing in Preventing PICC Dislodgement
tiistai 8. syyskuuta 2026 päivittänyt: Changi General Hospital
Evidence regarding clinical effectiveness and acceptability of PICC sleeves remain limited.
Few randomised controlled trials have evaluated PICC sleeves in routine hospital practice, and there is limited evidence regarding their feasibility, safety and influence on line condition.
This pilot randomised controlled trial aims to evaluate the feasibility, safety, and user experience of a protective PICC sleeve among hospitalised patients with PICCs.
Tutkimuksen yleiskatsaus
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
67
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Singapore, Singapore, 529889
- Changi General Hospital
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Adult patients receiving PICC placement for various medical conditions
Exclusion Criteria:
- Patients with known allergies to materials in the PICC sleeve
- Patients contraindicated for PICC placement
- Patients who are aggressive and/or restless
- Patients whose skin condition is unsuitable for CHG gel dressing application (e.g. skin with eczema plaques, bullous pemphigoid)
- Patients who have no mental capacity to give consent
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Ei väliintuloa: The control group
The control group used the standard securement dressing
|
|
|
Kokeellinen: The Treatment group
The treatment group received appropriately sized PICC sleeve cover in addition to standard device securement practices.
|
The novel PICC sleeve cover would be applied on the intervention group in addition to standard PICC securement practices.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Participant Recruitment Rate
Aikaikkuna: 16 months
|
Number of participants recruited over the recruitment period
|
16 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Intervention Adherence
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants who were compliant to wearing the PICC sleeve cover
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Retention of Study Participants across 3 Time-points
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Number of study participants across 3 time-points (2 days after PICC insertion, 14 days after PICC insertion or upon removal, whichever earlier, and 7 days after discharge from hospital) presented as a percentage of the original number of study participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Completeness of Data Collected
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of data collected over the ideal number of data to be collected
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Number of Adverse Events
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants suffering from adverse events over the total number of participants
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Dislodgement Risk
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived dislodgement risk on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Comfort Level
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived comfort level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Visibility Level
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived visibility level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
The visibility level refers to the degree the PICC dressing is exposed to the onlookers and how that may affect their own self-image.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported User-friendliness
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their perceived user-friendliness of the PICC dressing on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patient-Reported Acceptability Outcome
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
The mean of the mean scores for patient-reported dislodgement risk, comfort level, visibility level and user-friendliness.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Dislodgement Risk
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patients' perceived dislodgement risk on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Comfort Level
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patients' perceived comfort level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Visibility Level
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patient's perceived visibility level on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
The visibility level refers to the degree the PICC dressing is exposed to the onlookers and how that may affect their own self-image.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported User-friendliness
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Mean score of all participants rating their patient's perceived user-friendliness of the PICC dressing on a self-designed questionnaire from 1 (strongly disagree) to 5 (strongly agree) in each study arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Staff-Reported Acceptability Outcome
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
The mean of the mean scores for staff-reported dislodgement risk, comfort level, visibility level and user-friendliness.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Dislodgement Cases
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Number of dislodgement cases (complete/partial)
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Dressing Condition
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with intact dressing or dressing with some peeling over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
CHG Gel Condition
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with intact CHG gel or CHG gel with some swelling over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
External Length
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with the same or minimally changed (< 2cm) external length of PICC over the total number of participants in each arm.
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Patency of PICC Lumens
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants whose PICC are still patent with or without backflow over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Insertion Site
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants without any redness, slough or necrotic tissue at the insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Discharge from PICC insertion site
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with no discharge from the PICC insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
|
Surrounding Skin around PICC Insertion Site
Aikaikkuna: From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Percentage of participants with nil redness of surrounding skin around the PICC insertion site over the total number of participants in each arm
|
From enrolment to 7 days after discharge or upon removal, whichever earlier.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Chan RJ, Northfield S, Larsen E, Mihala G, Ullman A, Hancock P, Marsh N, Gavin N, Wyld D, Allworth A, Russell E, Choudhury MA, Flynn J, Rickard CM. Central venous Access device SeCurement And Dressing Effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial. Trials. 2017 Oct 4;18(1):458. doi: 10.1186/s13063-017-2207-x.
- O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee (HICPAC) (Appendix 1). Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin Infect Dis. 2011 May;52(9):1087-99. doi: 10.1093/cid/cir138. No abstract available.
- Karpanen T, Casey A, Whitehouse T, Nightingale P, Das I, Elliott TS. Abstracts from the 3rd International Conference on Prevention and Infection Control (ICPIC 2015). Antimicrob Resist Infect Control. 2015 Jun 16;4 Suppl 1(Suppl 1):I1-P308. doi: 10.1186/2047-2994-4-s1-i1. No abstract available.
- Dong H, Zhu Y, Zhang X, Yin X, Liu F. Chest CT tomography vs. intracavitary electrocardiogram guidance in predicting the length of PICC placement. BMC Surg. 2022 May 19;22(1):197. doi: 10.1186/s12893-022-01604-0.
- Grau D, Clarivet B, Lotthe A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017 Jan 28;6:18. doi: 10.1186/s13756-016-0161-0. eCollection 2017.
- Moureau N, Lamperti M, Kelly LJ, Dawson R, Elbarbary M, van Boxtel AJ, Pittiruti M. Evidence-based consensus on the insertion of central venous access devices: definition of minimal requirements for training. Br J Anaesth. 2013 Mar;110(3):347-56. doi: 10.1093/bja/aes499. Epub 2013 Jan 29.
- Yu K, Li J, Zhang D, Liu B, Wang K, Liu W, Shi Y, Zhao Y, Liu Y, Guo N, Sun W. Types of peripherally inserted central catheters and the risk of unplanned removals in patients: A prospective cohort study. Int J Nurs Stud. 2024 Jan;149:104621. doi: 10.1016/j.ijnurstu.2023.104621. Epub 2023 Oct 12.
- Xu B, Zhang J, Hou J, Ma M, Gong Z, Tang S. Nurses' Attitudes and Knowledge of Peripherally Inserted Central Catheter Maintenance in Primary Hospitals in China: A Cross-Sectional Survey. Risk Manag Healthc Policy. 2020 Jul 28;13:903-913. doi: 10.2147/RMHP.S250741. eCollection 2020.
- Rickard CM, Marsh NM, Webster J, Gavin NC, Chan RJ, McCarthy AL, Mollee P, Ullman AJ, Kleidon T, Chopra V, Zhang L, McGrail MR, Larsen E, Choudhury MA, Keogh S, Alexandrou E, McMillan DJ, Mervin MC, Paterson DL, Cooke M, Ray-Barruel G, Castillo MI, Hallahan A, Corley A, Geoffrey Playford E. Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. BMJ Open. 2017 Jun 15;7(6):e015291. doi: 10.1136/bmjopen-2016-015291.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Torstai 21. maaliskuuta 2024
Ensisijainen valmistuminen (Todellinen)
Torstai 10. heinäkuuta 2025
Opintojen valmistuminen (Todellinen)
Torstai 25. syyskuuta 2025
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Keskiviikko 2. syyskuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 8. syyskuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Maanantai 14. syyskuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Maanantai 14. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 8. syyskuuta 2026
Viimeksi vahvistettu
Maanantai 1. syyskuuta 2025
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- 2024-2117
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
IPD-suunnitelman kuvaus
Legal/Regulatory: Data protection laws, consent limitations, institutional policies
Commercial: Proprietary concerns, competitive advantage, patent issues
Ethical: Privacy concerns, insufficient original consent, ethics approval scope
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .